Shinwari Muhammad Saad, Tanwir Farzeen, Hyder Pakiza Raza, Bin Saeed Muhammad Humza
Department of Periodontology, Pakistan Air Force Hospital, Islamabad.
Department of Periodontology, Ziauddin University, Karachi.
J Coll Physicians Surg Pak. 2014 Sep;24(9):676-84.
Host Modulation Therapy (HMT) is a treatment concept that reduces tissue destruction and stabilizes or even regenerates inflammatory tissue by modifying host response factors. It has been used for treating osteoporosis and arthritis for several decades. However, its use in dentistry has only been recently reported. The objective of this article is to present a review of the various literatures available on HMT and also its role as adjunct therapy in periodontics. For identifying studies for this review, a PUBMED search was carried out in 2013 for all articles published till December 2012. The search was restricted to English language publications only. Longitudinal prospective and retrospective studies were included in the search. The key words used were: Host Modulation Therapy; Sub antimicrobial dose doxycycline and Non-Surgical Periodontal Therapy. The main outcomes sought were host modulation therapeutics in periodontics. Exclusion criteria included cross sectional studies, short case series as well as studies with short follow-up periods. There is a paucity of literature on HMT in periodontics although the only drug approved by United States Food and Drug Administration (FDA) is a subantimicrobial dose of doxycycline (SDD) with highly predictable results as a host modulating agent in periodontal diseases and also an effective adjunctive therapy in various diseases of periodontium. However, more randomized controlled trials are needed to obtain clinical guidelines on the usage of other host modulating agents as adjunct as well as definite therapy for periodontal diseases. SDD is an effective adjunct therapy when used in dosage of 20mg twice daily for minimum 3 months duration in various periodontal diseases with predictable clinical outcomes. It is also recommended that future clinical research on anti cytokine drugs, chemically modified tetracycline and other HMT agents should be conducted so that new drugs are available with highly predictable results.
宿主调控疗法(HMT)是一种治疗理念,通过改变宿主反应因子来减少组织破坏,并使炎症组织稳定甚至再生。它已用于治疗骨质疏松症和关节炎数十年。然而,其在牙科领域的应用直到最近才被报道。本文的目的是综述关于HMT的各种现有文献,以及其在牙周病学中作为辅助治疗的作用。为了确定本综述的研究,2013年在PUBMED上搜索了截至2012年12月发表的所有文章。搜索仅限于英文出版物。纵向前瞻性和回顾性研究都被纳入搜索范围。使用的关键词为:宿主调控疗法;亚抗菌剂量多西环素和非手术牙周治疗。主要寻求的结果是牙周病学中的宿主调控疗法。排除标准包括横断面研究、短病例系列以及随访期短的研究。尽管美国食品药品监督管理局(FDA)批准的唯一药物是亚抗菌剂量的多西环素(SDD),其作为牙周疾病的宿主调节剂具有高度可预测的结果,并且在各种牙周疾病中也是一种有效的辅助治疗,但关于HMT在牙周病学方面的文献仍然匮乏。然而,需要更多的随机对照试验来获得关于使用其他宿主调节剂作为辅助治疗以及牙周疾病明确治疗的临床指南。在各种牙周疾病中使用SDD,每天两次,每次20mg,至少持续3个月,是一种有效的辅助治疗,具有可预测的临床结果。还建议未来应对抗细胞因子药物、化学修饰四环素和其他HMT药物进行临床研究,以便获得具有高度可预测结果的新药。